Record Fiscal 2024 Revenue of $5.00 Billion, up 2.4% YoY as Reported and 2.7% YoYin Constant Currency(1) Successfully Achieved Accelerated Profitability Improvement Targets Initiates Fiscal 2025 Outlook: Sharpening Focus on Strategic Priorities while Phasing Out Certain Non-Core, Low Margin Business Activities As a Result of which Expects Fiscal 2025 Revenue Outlook of (10.9)%-(7.7)% YoY as Reported and 1%-4.5% YoY in Pro Forma(2) Constant Currency(1) Targeting Double-Digit Total Shareholder Returns(3)(4), Supported by Enhanced Profitability Improvement Board Approves 10% Increase of Quarterly Cash Dividend(4) Full Year Fiscal 2024 Highlights (All comparisons are against the prior year) Record revenue of $5,005 million, up 2.4% as reported and up 2.7% in constant currency(1), including record revenue of $3,326 million in North America, record revenue of $726 million in Europe and record revenue of $953 million in Rest of World
Record managed services revenue of $2,905 million, equivalent to approximately 58% of total revenue
GAAP diluted EPS of $4.25, down 5.3%, including a restructuring charge of 98 cents per share, without which GAAP diluted EPS was $5.23
Non-GAAP diluted EPS of $6.44, up 9.0%
Free cash flow of $619 million, comprised of cash flow from operations of $724 million, less $105 million in net capital expenditures and other(5), and including $75 million of restructuring payments not assumed in full year free cash flow guidance of $700 million
Repurchased $563 million of ordinary shares during the fiscal year
Twelve-month backlog of $4.06 billion; adjusting comparable periods for the phase out of certain business activities, twelve-month backlog was up 2.5%(2) as compared to last year's fourth fiscal quarter, and up approximately $30 million(2) sequentially
Fourth Quarter Fiscal 2024 Highlights (All comparisons are against the prior year) Record revenue of $1,264 million, up 1.7% as reported and up 2.1% in constant currency(1); revenue was slightly above the midpoint of the $1,240-$1,280 million guidance range, adjusting for a positive impact from foreign currency movements of approximately $3 million compared to our guidance assumptions
GAAP diluted EPS of $0.76, including a restructuring charge of 0.64 cents per share, without which GAAP diluted EPS would have been at the higher end of the guidance range of $1.34-$1.42
Non-GAAP diluted EPS of $1.70, at the midpoint of the guidance range of $1.67-$1.73
GAAP operating income of $113 million, including a restructuring charge of $83 million; GAAP operating margin of 8.9%, down 230 basis points as compared to last year's fourth fiscal quarter and down 520 basis points sequentially
Non-GAAP operating income of $236 million; non-GAAP operating margin of 18.7%, up 90 basis points as compared to last year's fourth fiscal quarter and up 10 basis points sequentially, reflecting a continued focus on operational excellence
The Board of Directors (the "Board") approved a 10% increase in the Company's quarterly cash dividend payment from $0.479 per share to $0.527 per share, anticipated to be first paid in April 2025, subject to shareholder approval at the January 2025 annual meeting
1. Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
2. For comparison purposes, pro forma adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook
3. Expected total shareholder return assumes midpoint of fiscal year 2025 non-GAAP EPS growth outlook, plus dividend yield
4. Subject to shareholder approval at January 2025 annual meeting
5. Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding) JERSEY CITY, NJ / ACCESSWIRE / November 12, 2024 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended September 30, 2024. "Fiscal 2024 was another important year in our journey as we continued to serve many of the world's largest communication service providers with the innovation they need to accelerate their journey to the cloud, enhance customer experience, monetize next generation networks, and to digitalize and automate their mission critical operations. We delivered strong double-digit growth in cloud, achieved a record year in managed services, and accelerated our profitability, all within the backdrop of a challenging industry demand environment. The year closed with strong sales momentum which included a significant award to deploy our next-gen monetization platform for a major US customer, and new cloud migration deals with Vodafone Italy and NTT Infranet in Japan. Additionally, we have continued to enhance our generative AI platform, amAIz, with new capabilities that leverage NVIDIA AI to deliver immersive customer experiences with real-time interaction and visualization," said Shuky Sheffer, president and chief executive officer of Amdocs Management Limited. "Consistent with our full year guidance, we delivered accelerated profitability improvement in fiscal 2024 as we focused on operational excellence and the benefits of automation and artificial intelligence to drive internal efficiency. We continue to invest in our strategic priorities, while at the same time optimizing the portfolio of products, services, and business activities. Thus, in fiscal 2025, we are phasing out several low-margin, non-core business activities that are becoming commoditized and hold little potential for long-term value addition or profitability enhancement. We believe these actions will reinforce our level of business visibility, including a higher share of revenue from long-term managed services engagements. This move is also expected to sharpen our focus on higher-margin strategic priorities like cloud, monetization platforms and Gen AI where we are well placed to lead the communications industry through our commitment to innovation," said Tamar Rapaport-Dagim, chief financial officer & chief operating officer of Amdocs Management Limited. Sheffer concluded, "We enter fiscal 2025 as an industry leader with a unique competitive position, strong 12-month backlog visibility, and a high win rate. Moreover, we believe Amdocs is well positioned to monetize a healthy pipeline of market opportunities while navigating a continuously challenging demand environment. Adjusting for the phase out of several low-margin, non-core business activities, we expect pro forma(2) revenue growth of between 1% to 4.5% in constant currency(1) in fiscal 2025, as well as another year of double-digit growth in cloud. We also anticipate significantly higher operating profitability and robust earnings to cash conversion, underpinning the delivery of double-digit expected total shareholder returns(3) for the fifth consecutive year, including our dividend yield." Revenue (All comparisons are against the prior year period)
|
| In millions
|
|
|
| Three months ended
|
|
| Twelve months ended
|
|
|
| September 30, 2024
|
|
| September 30, 2024
|
|
|
| Actual
|
|
| Previous
Guidance
|
|
| Actual
|
|
| Previous
Guidance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
| $
| 1,264
|
|
| $ 1,240-$1,280
|
|
| $
| 5,005
|
|
|
| -
|
| Revenue Growth, as reported |
| 1.7%
|
|
|
|
| -
|
|
| 2.4%
|
|
| 1.9%-2.7%
|
| Revenue Growth, constant currency (1) |
| 2.1%
|
|
|
|
| -
|
|
| 2.7%
|
|
| 2.3%-3.1%
|
|
Revenue for the fourth fiscal quarter of 2024 was slightly above the midpoint of Amdocs' guidance, adjusting for positive impact from foreign currency movements of approximately $3 million relative to our guidance assumptions and relative to the third quarter of fiscal 2024
Revenue for the full year fiscal 2024 includes an unfavorable impact from foreign currency movements of approximately 0.3% year-over-year
Net Income and Earnings Per Share
|
| In thousands, expect per share data
|
|
|
| Three months ended
|
|
| Twelve months ended
|
|
|
| September 30,
|
|
| September 30,
|
|
|
| 2024
|
|
| 2023
|
|
| 2024
|
|
| 2023
|
| GAAP Measures |
|
|
|
|
|
|
|
|
|
|
|
| Net Income |
| $
| 87,176
|
|
| $
| 102,666
|
|
| $
| 496,321
|
|
| $
| 542,962
|
| Net Income attributable to Amdocs Limited |
| $
| 86,441
|
|
| $
| 102,011
|
|
| $
| 493,197
|
|
| $
| 540,709
|
| Diluted earnings per share |
| $
| 0.76
|
|
| $
| 0.86
|
|
| $
| 4.25
|
|
| $
| 4.49
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-GAAP Measures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-GAAP Net Income |
| $
| 195,668
|
|
| $
| 169,009
|
|
| $
| 750,928
|
|
| $
| 714,454
|
| Non-GAAP Net Income attributable to Amdocs Limited |
| $
| 194,933
|
|
| $
| 168,354
|
|
| $
| 747,804
|
|
| $
| 712,201
|
| Non-GAAP Diluted earnings per share |
| $
| 1.70
|
|
| $
| 1.42
|
|
| $
| 6.44
|
|
| $
| 5.91
|
|
Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below.
Capital Allocation Quarterly Cash Dividend Program: On November 12, 2024, the Board approved the Company's next quarterly cash dividend payment of $0.479 per share, and set December 31, 2024 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on January 31, 2025
The Board also approved a 10% increase in the Company's quarterly cash dividend payment to $0.527 per share, which is anticipated to be first paid in April 2025, provided that the increase is approved by shareholders at the January 2025 annual general meeting of shareholders
Share Repurchase Activity: Repurchased $120 million of ordinary shares during the fourth quarter of fiscal 2024
Twelve-month Backlog Twelve-month backlog was $4.06 billion at the end of the fourth quarter of fiscal 2024. On a pro forma(2) basis, adjusting the comparable period for the phase out of certain business activities, twelve-month backlog was up approximately 2.5% as compared to last year's fourth fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities. First Quarter Fiscal 2025 Outlook
|
|
|
|
|
| In millions, expect per share data
|
|
|
| Q1 - 2025
|
| Revenue |
| $ 1,095-$1,135
|
| GAAP Diluted earnings per share |
| $ 1.20-$1.29
|
| Non-GAAP Diluted earnings per share |
| $ 1.61-$1.67
|
|
First quarter revenue guidance assumes favorable $2 million sequential impact from foreign currency fluctuations as compared to the fourth quarter of fiscal 2024
First quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.20-$0.22 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.11 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
GAAP diluted EPS guidance does not include the impact of future restructuring charges
Full Year Fiscal 2025 Outlook |
|
|
| |
| FY 2025 - Year-over -Year growth
|
| Revenue Growth, as reported |
| (10.9)%-(7.7)%
|
| Revenue Growth, Pro forma (2) constant currency (1) |
| 1%-4.5%
|
| GAAP Diluted earnings per share |
| 25.0%-33.0%
|
| Non-GAAP Diluted earnings per share |
| 6.5%-10.5%
|
|
|
|
|
|
| |
| In millions
FY 2025
|
| Free Cash Flow (5) |
| $ 710-$730
|
|
Revenue growth on a pro forma(2), constant currency(1) basis adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of several low-margin, non-core business activities, including certain low-margin software and hardware partner activities, Vubiquity's transactional video on demand business and non-core subscription services; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook
Full year fiscal 2025 revenue guidance incorporates an expected favorable impact from foreign currency fluctuations of approximately 0.2% year-over-year, and includes some inorganic contribution
Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.86-$0.94 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.43 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
GAAP diluted EPS guidance does not include the impact of future restructuring charges
Non-GAAP operating margin is anticipated to be within a range of 21.1% to 21.7% for the full year fiscal 2025
Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value
Non-GAAP effective tax rate is anticipated to be within a range of 15% to 17% for the full year fiscal 2025
Free cash flow(5) is comprised of cash flow from operations, less net capital expenditures and other, and excludes payments related to restructuring charges
The forward looking statements regarding our first fiscal quarter 2025 and full year fiscal 2025 guidance take into consideration the Company's current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. Conference Call and Earnings Webcast Presentation Details Amdocs will host a conference call and earnings webcast presentation on November 12, 2024 at 5:00 p.m. Eastern Time to discuss the Company's fourth quarter of fiscal 2024 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast. Non-GAAP Financial Measures
This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items: amortization of purchased intangible assets and other acquisition-related costs;
changes in certain acquisition-related liabilities measured at fair value;
restructuring and unusual charges or benefits;
equity-based compensation expense;
other; and
tax effects related to the above.
Free cash flow equals cash generated by operating activities less net capital expenditures and other. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow(5), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business. For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items. Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below. Supporting Resources About Amdocs Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $5.00 billion in fiscal 2024. For more information, visit Amdocs at www.amdocs.com. This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023 and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024, the second quarter of fiscal 2024 filed on May 20, 2024 and for the third quarter of fiscal 2024 on August 19, 2024. Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data) |
| Three months ended
September 30,
|
|
| Fiscal year ended
September 30,
|
| |
| 2024
|
|
| 2023
|
|
| 2024
|
|
| 2023
|
| Revenue |
| $
| 1,263,882
|
|
| $
| 1,242,564
|
|
| $
| 5,004,989
|
|
| $
| 4,887,550
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
|
| 824,888
|
|
|
| 803,600
|
|
|
| 3,249,598
|
|
|
| 3,159,941
|
| Research and development |
|
| 90,069
|
|
|
| 97,693
|
|
|
| 360,798
|
|
|
| 374,855
|
| Selling, general and administrative |
|
| 138,705
|
|
|
| 140,380
|
|
|
| 572,845
|
|
|
| 570,707
|
| Amortization of purchased intangible assets and other |
|
| 14,333
|
|
|
| 15,601
|
|
|
| 62,052
|
|
|
| 57,156
|
| Restructuring charges |
|
| 83,213
|
|
|
| 46,365
|
|
|
| 131,088
|
|
|
| 70,901
|
| |
|
| 1,151,208
|
|
|
| 1,103,639
|
|
|
| 4,376,381
|
|
|
| 4,233,560
|
| Operating income |
|
| 112,674
|
|
|
| 138,925
|
|
|
| 628,608
|
|
|
| 653,990
|
| Interest and other expense, net |
|
| (9,237
| )
|
|
| (5,307
| )
|
|
| (37,537
| )
|
|
| (17,629
| )
| Income before income taxes |
|
| 103,437
|
|
|
| 133,618
|
|
|
| 591,071
|
|
|
| 636,361
|
| Income taxes |
|
| 16,261
|
|
|
| 30,952
|
|
|
| 94,750
|
|
|
| 93,399
|
| Net income |
| $
| 87,176
|
|
| $
| 102,666
|
|
| $
| 496,321
|
|
| $
| 542,962
|
| Net income attributable to noncontrolling interests |
|
| 735
|
|
|
| 655
|
|
|
| 3,124
|
|
|
| 2,253
|
| Net income attributable to Amdocs Limited |
| $
| 86,441
|
|
| $
| 102,011
|
|
| $
| 493,197
|
|
| $
| 540,709
|
| Basic earnings per share attributable to Amdocs Limited |
| $
| 0.76
|
|
| $
| 0.86
|
|
| $
| 4.27
|
|
| $
| 4.52
|
| Diluted earnings per share attributable to Amdocs Limited |
| $
| 0.76
|
|
| $
| 0.86
|
|
| $
| 4.25
|
|
| $
| 4.49
|
| Basic weighted average number of shares outstanding |
|
| 113,745
|
|
|
| 118,076
|
|
|
| 115,489
|
|
|
| 119,687
|
| Diluted weighted average number of shares outstanding |
|
| 114,378
|
|
|
| 118,884
|
|
|
| 116,145
|
|
|
| 120,519
|
| Cash dividends declared per share |
| $
| 0.479
|
|
| $
| 0.435
|
|
| $
| 1.872
|
|
| $
| 1.700
|
|
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
|
| Three months ended
September 30,
|
|
| Fiscal year ended
September 30,
|
| |
| 2024
|
|
| 2023
|
|
| 2024
|
|
| 2023
|
| |
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
| $
| 1,263,882
|
|
| $
| 1,242,564
|
|
| $
| 5,004,989
|
|
| $
| 4,887,550
|
| Non-GAAP operating income |
|
| 236,223
|
|
|
| 221,105
|
|
|
| 923,288
|
|
|
| 868,602
|
| Non-GAAP net income |
|
| 195,668
|
|
|
| 169,009
|
|
|
| 750,928
|
|
|
| 714,454
|
| Non-GAAP net income attributable to Amdocs Limited |
|
| 194,933
|
|
|
| 168,354
|
|
|
| 747,804
|
|
|
| 712,201
|
| Non-GAAP diluted earnings per share |
| $
| 1.70
|
|
| $
| 1.42
|
|
| $
| 6.44
|
|
| $
| 5.91
|
| Diluted weighted average number of shares outstanding |
|
| 114,378
|
|
|
| 118,884
|
|
|
| 116,145
|
|
|
| 120,519
|
|
Free Cash Flows
(In thousands) |
| Three months ended
September 30,
|
|
| Fiscal year ended
September 30,
|
| |
| 2024
|
|
| 2023
|
|
| 2024
|
|
| 2023
|
| |
|
|
|
|
|
|
|
|
|
|
|
| Net Cash Provided by Operating Activities |
| $
| 217,922
|
|
| $
| 272,371
|
|
| $
| 724,428
|
|
| $
| 822,630
|
| Purchases of property and equipment, net (a) |
|
| (25,812
| )
|
|
| (26,557
| )
|
|
| (105,495
| )
|
|
| (124,362
| )
| Free Cash Flow |
| $
| 192,110
|
|
| $
| 245,814
|
|
| $
| 618,933
|
|
| $
| 698,268
|
|
(a) The amounts under "Purchase of property and equipment, net" include immaterial proceeds from sale of property and equipment for the fiscal years ended September 30, 2024 and 2023, respectively. AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands) |
| Three Months Ended September 30, 2024
|
| |
| GAAP
|
|
| Amortization of purchased intangible assets and other
|
|
| Equity based compensation expense
|
|
| Restructuring charges
|
|
| Other
|
|
| Tax
effect
|
|
| Non-GAAP
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
| $
| 824,888
|
|
| $
| -
|
|
| $
| (13,283
| )
|
| $
| -
|
|
| $
| -
|
|
| $
| -
|
|
| $
| 811,605
|
| Research and development |
|
| 90,069
|
|
|
|
|
|
|
| (2,355
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 87,714
|
| Selling, general and administrative |
|
| 138,705
|
|
|
|
|
|
|
| (10,365
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 128,340
|
| Amortization of purchased intangible assets and other |
|
| 14,333
|
|
|
| (14,333
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -
|
| Restructuring charges |
|
| 83,213
|
|
|
|
|
|
|
|
|
|
|
| (83,213
| )
|
|
|
|
|
|
|
|
|
|
| -
|
| Total operating expenses |
|
| 1,151,208
|
|
|
| (14,333
| )
|
|
| (26,003
| )
|
|
| (83,213
| )
|
|
|
|
|
|
|
|
|
|
| 1,027,659
|
| Operating income |
|
| 112,674
|
|
|
| 14,333
|
|
|
| 26,003
|
|
|
| 83,213
|
|
|
|
|
|
|
|
|
|
|
| 236,223
|
| Interest and other expense, net |
|
| (9,237
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2,549
|
|
|
|
|
|
|
| (6,688
| )
| Income taxes |
|
| 16,261
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 17,606
|
|
|
| 33,867
|
| Net income |
|
| 87,176
|
|
|
| 14,333
|
|
|
| 26,003
|
|
|
| 83,213
|
|
|
| 2,549
|
|
|
| (17,606
| )
|
|
| 195,668
|
| Net income attributable to noncontrolling interests |
|
| 735
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 735
|
| Net income attributable to Amdocs Limited |
| $
| 86,441
|
|
| $
| 14,333
|
|
| $
| 26,003
|
|
| $
| 83,213
|
|
| $
| 2,549
|
|
| $
| (17,606
| )
|
| $
| 194,933
|
|
|
| Three Months Ended September 30, 2023
|
| |
| GAAP
|
|
| Amortization of purchased intangible assets and other
|
|
| Equity based compensation expense
|
|
| Changes in certain acquisitions related liabilities measured at fair value
|
|
| Restructuring charges
|
|
| Other
|
|
| Tax
effect
|
|
| Non-GAAP
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
| $
| 803,600
|
|
| $
| -
|
|
| $
| (12,401
| )
|
| $
| 4,579
|
|
| $
| -
|
|
| $
| -
|
|
| $
| -
|
|
| $
| 795,778
|
| Research and development |
|
| 97,693
|
|
|
|
|
|
|
| (2,285
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 95,408
|
| Selling, general and administrative |
|
| 140,380
|
|
|
|
|
|
|
| (10,107
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 130,273
|
| Amortization of purchased intangible assets and other |
|
| 15,601
|
|
|
| (15,601
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -
|
| Restructuring charges |
|
| 46,365
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (46,365
| )
|
|
|
|
|
|
|
|
|
|
| -
|
| Total operating expenses |
|
| 1,103,639
|
|
|
| (15,601
| )
|
|
| (24,793
| )
|
|
| 4,579
|
|
|
| (46,365
| )
|
|
|
|
|
|
|
|
|
|
| 1,021,459
|
| Operating income |
|
| 138,925
|
|
|
| 15,601
|
|
|
| 24,793
|
|
|
| (4,579
| )
|
|
| 46,365
|
|
|
|
|
|
|
|
|
|
|
| 221,105
|
| Interest and other expense, net |
|
| (5,307
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 398
|
|
|
|
|
|
|
| (4,909
| )
| Income taxes |
|
| 30,952
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 16,235
|
|
|
| 47,187
|
| Net income |
|
| 102,666
|
|
|
| 15,601
|
|
|
| 24,793
|
|
|
| (4,579
| )
|
|
| 46,365
|
|
|
| 398
|
|
|
| (16,235
| )
|
|
| 169,009
|
| Net income attributable to noncontrolling interests |
|
| 655
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 655
|
| Net income attributable to Amdocs Limited |
| $
| 102,011
|
|
| $
| 15,601
|
|
| $
| 24,793
|
|
| $
| (4,579
| )
|
| $
| 46,365
|
|
| $
| 398
|
|
| $
| (16,235
| )
|
| $
| 168,354
|
|
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands) |
| Fiscal year ended September 30,2024
|
| |
| GAAP
|
|
| Amortization of purchased intangible assets and other
|
|
| Equity based compensation expense
|
|
| Changes in certain acquisitions related liabilities measured at fair value
|
|
| Restructuring charges
|
|
| Other
|
|
| Tax
effect
|
|
| Non-GAAP
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
| $
| 3,249,598
|
|
| $
| -
|
|
| $
| (53,409
| )
|
| $
| 3,000
|
|
| $
| -
|
|
| $
| -
|
|
| $
| -
|
|
| $
| 3,199,189
|
| Research and development |
|
| 360,798
|
|
|
|
|
|
|
| (8,644
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 352,154
|
| Selling, general and administrative |
|
| 572,845
|
|
|
|
|
|
|
| (42,487
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 530,358
|
| Amortization of purchased intangible assets and other |
|
| 62,052
|
|
|
| (62,052
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -
|
| Restructuring charges |
|
| 131,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (131,088
| )
|
|
|
|
|
|
|
|
|
|
| -
|
| Total operating expenses |
|
| 4,376,381
|
|
|
| (62,052
| )
|
|
| (104,540
| )
|
|
| 3,000
|
|
|
| (131,088
| )
|
|
|
|
|
|
|
|
|
|
| 4,081,701
|
| Operating income |
|
| 628,608
|
|
|
| 62,052
|
|
|
| 104,540
|
|
|
| (3,000
| )
|
|
| 131,088
|
|
|
|
|
|
|
|
|
|
|
| 923,288
|
| Interest and other expense, net |
|
| (37,537
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8,087
|
|
|
|
|
|
|
| (29,450
| )
| Income taxes |
|
| 94,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 48,160
|
|
|
| 142,910
|
| Net income |
|
| 496,321
|
|
|
| 62,052
|
|
|
| 104,540
|
|
|
| (3,000
| )
|
|
| 131,088
|
|
|
| 8,087
|
|
|
| (48,160
| )
|
|
| 750,928
|
| Net income attributable to noncontrolling interests |
|
| 3,124
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3,124
|
| Net income attributable to Amdocs Limited |
| $
| 493,197
|
|
| $
| 62,052
|
|
| $
| 104,540
|
|
| $
| (3,000
| )
|
| $
| 131,088
|
|
| $
| 8,087
|
|
| $
| (48,160
| )
|
| $
| 747,804
|
|
|
| Fiscal year ended September 30,2023
|
|
|
|
| |
| GAAP
|
|
| Amortization of purchased intangible assets and other
|
|
| Equity based compensation expense
|
|
| Changes in certain acquisitions related liabilities measured at fair value
|
|
| Restructuring charges
|
|
| Other
|
|
| Tax
effect
|
|
| Non-GAAP
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
| $
| 3,159,941
|
|
| $
| -
|
|
| $
| (42,969
| )
|
| $
| 3,143
|
|
| $
| -
|
|
| $
| -
|
|
| $
| -
|
|
| $
| 3,120,115
|
| Research and development |
|
| 374,855
|
|
|
|
|
|
|
| (7,509
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 367,346
|
| Selling, general and administrative |
|
| 570,707
|
|
|
|
|
|
|
| (39,220
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 531,487
|
| Amortization of purchased intangible assets and other |
|
| 57,156
|
|
|
| (57,156
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -
|
| Restructuring charges |
|
| 70,901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (70,901
| )
|
|
|
|
|
|
|
|
|
|
| -
|
| Total operating expenses |
|
| 4,233,560
|
|
|
| (57,156
| )
|
|
| (89,698
| )
|
|
| 3,143
|
|
|
| (70,901
| )
|
|
|
|
|
|
|
|
|
|
| 4,018,948
|
| Operating income |
|
| 653,990
|
|
|
| 57,156
|
|
|
| 89,698
|
|
|
| (3,143
| )
|
|
| 70,901
|
|
|
|
|
|
|
|
|
|
|
| 868,602
|
| Interest and other expense, net |
|
| (17,629
| )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 906
|
|
|
|
|
|
|
| (16,723
| )
| Income taxes |
|
| 93,399
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 44,026
|
|
|
| 137,425
|
| Net income |
|
| 542,962
|
|
|
| 57,156
|
|
|
| 89,698
|
|
|
| (3,143
| )
|
|
| 70,901
|
|
|
| 906
|
|
|
| (44,026
| )
|
|
| 714,454
|
| Net income attributable to noncontrolling interests |
|
| 2,253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2,253
|
| Net income attributable to Amdocs Limited |
| $
| 540,709
|
|
| $
| 57,156
|
|
| $
| 89,698
|
|
| $
| (3,143
| )
|
| $
| 70,901
|
|
| $
| 906
|
|
| $
| (44,026
| )
|
| $
| 712,201
|
|
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
|
| As of
|
|
|
| September 30,
2024
|
|
| September 30,
2023
|
| ASSETS |
|
|
|
|
|
| Current assets: |
|
|
|
|
|
| Cash and cash equivalents |
| $
| 346,085
|
|
| $
| 520,080
|
| Short-term interest-bearing investments |
|
| 168,242
|
|
|
| 222,451
|
| Accounts receivable, net, including unbilled |
|
| 1,028,357
|
|
|
| 944,477
|
| Prepaid expenses and other current assets |
|
| 228,498
|
|
|
| 224,622
|
| Total current assets |
|
| 1,771,182
|
|
|
| 1,911,630
|
| |
|
|
|
|
|
|
|
| Property and equipment, net |
|
| 755,601
|
|
|
| 790,923
|
| Lease assets |
|
| 149,254
|
|
|
| 160,938
|
| Goodwill and other intangible assets, net |
|
| 3,005,637
|
|
|
| 2,930,580
|
| Other noncurrent assets |
|
| 704,468
|
|
|
| 631,582
|
| Total assets |
| $
| 6,386,142
|
|
| $
| 6,425,653
|
| |
|
|
|
|
|
|
|
| LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Current liabilities |
|
|
|
|
|
|
|
| Accounts payable, accruals and other |
| $
| 1,315,679
|
|
| $
| 1,142,781
|
| Lease liabilities |
|
| 39,983
|
|
|
| 39,960
|
| Deferred revenue |
|
| 115,247
|
|
|
| 170,634
|
| Total current liabilities |
|
| 1,470,909
|
|
|
| 1,353,375
|
| Lease liabilities |
|
| 103,462
|
|
|
| 121,654
|
| Long-term debt, net of unamortized debt issuance costs |
|
| 646,291
|
|
|
| 645,696
|
| Other noncurrent liabilities |
|
| 666,303
|
|
|
| 737,996
|
| Total Amdocs Limited Shareholders' equity |
|
| 3,456,976
|
|
|
| 3,523,759
|
| Noncontrolling interests |
|
| 42,201
|
|
|
| 43,173
|
| Total equity |
|
| 3,499,177
|
|
|
| 3,566,932
|
| Total liabilities and equity |
| $
| 6,386,142
|
|
| $
| 6,425,653
|
|
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
|
| Fiscal year ended
September 30,
|
| |
| 2024
|
|
| 2023
|
| Cash Flow from Operating Activities: |
|
|
|
|
|
| Net income |
| $
| 496,321
|
|
| $
| 542,962
|
| Reconciliation of net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
| Depreciation, amortization and impairment |
|
| 193,066
|
|
|
| 195,701
|
| Amortization of debt issuance cost |
|
| 596
|
|
|
| 579
|
| Equity-based compensation expense |
|
| 104,540
|
|
|
| 89,698
|
| Deferred income taxes |
|
| (45,673
| )
|
|
| (60,212
| )
| Loss from short-term interest-bearing investments |
|
| 5,576
|
|
|
| 2,762
|
| Net changes in operating assets and liabilities, net of amounts acquired: |
|
|
|
|
|
|
|
| Accounts receivable, net |
|
| (104,413
| )
|
|
| 3,457
|
| Prepaid expenses and other current assets |
|
| (8,478
| )
|
|
| 7,891
|
| Other noncurrent assets |
|
| (2,250
| )
|
|
| (1,532
| )
| Lease assets and liabilities, net |
|
| (6,485
| )
|
|
| (4,144
| )
| Accounts payable, accrued expenses and accrued personnel |
|
| 216,324
|
|
|
| 158,876
|
| Deferred revenue |
|
| (60,332
| )
|
|
| (157,829
| )
| Income taxes payable, net |
|
| (47,241
| )
|
|
| (11,596
| )
| Other noncurrent liabilities |
|
| (17,123
| )
|
|
| 56,017
|
| Net cash provided by operating activities |
|
| 724,428
|
|
|
| 822,630
|
| Cash Flow from Investing Activities: |
|
|
|
|
|
|
|
| Purchase of property and equipment, net(a) |
|
| (105,495
| )
|
|
| (124,362
| )
| Proceeds from sale of short-term interest-bearing investments |
|
| 68,659
|
|
|
| 25,984
|
| Purchase of short-term interest-bearing investments |
|
| (9,061
| )
|
|
| -
|
| Net cash paid for business and intangible assets acquisitions |
|
| (86,824
| )
|
|
| (121,818
| )
| Other |
|
| 5,315
|
|
|
| (4,301
| )
| Net cash used in investing activities |
|
| (127,406
| )
|
|
| (224,497
| )
| Cash Flow from Financing Activities: |
|
|
|
|
|
|
|
| Repurchase of shares |
|
| (563,121
| )
|
|
| (489,524
| )
| Proceeds from employee stock option exercises |
|
| 26,949
|
|
|
| 48,681
|
| Payments of dividends |
|
| (211,967
| )
|
|
| (199,460
| )
| Distribution to noncontrolling interests |
|
| (4,096
| )
|
|
| (1,589
| )
| Payment of contingent consideration from a business acquisition |
|
| (18,782
| )
|
|
| (9,538
| )
| Net cash used in financing activities |
|
| (771,017
| )
|
|
| (651,430
| )
| Net decrease in cash and cash equivalents |
|
| (173,995
| )
|
|
| (53,297
| )
| Cash and cash equivalents at beginning of year |
|
| 520,080
|
|
|
| 573,377
|
| Cash and cash equivalents at end of year |
| $
| 346,085
|
|
| $
| 520,080
|
|
AMDOCS LIMITED
Supplementary Information
(In millions) |
| Three months ended
|
| |
| September 30,
|
|
| June 30,
|
|
| March 31,
|
|
| December 31,
|
|
| September 30,
|
| |
| 2024
|
|
| 2024
|
|
| 2024
|
|
| 2023
|
|
| 2023
|
| North America |
| $
| 835.8
|
|
| $
| 828.8
|
|
| $
| 823.2
|
|
| $
| 838.1
|
|
| $
| 834.4
|
| Europe |
|
| 184.1
|
|
|
| 175.9
|
|
|
| 184.8
|
|
|
| 181.4
|
|
|
| 175.5
|
| Rest of the World |
|
| 244.0
|
|
|
| 245.3
|
|
|
| 237.8
|
|
|
| 225.7
|
|
|
| 232.6
|
| Total Revenue |
| $
| 1,263.9
|
|
| $
| 1,250.1
|
|
| $
| 1,245.8
|
|
| $
| 1,245.2
|
|
| $
| 1,242.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Three months ended
|
| |
| September 30,
|
|
| June 30,
|
|
| March 31,
|
|
| December 31,
|
|
| September 30,
|
| |
| 2024
|
|
| 2024
|
|
| 2024
|
|
| 2023
|
|
| 2023
|
| Managed Services Revenue |
| $
| 721.4
|
|
| $
| 740.8
|
|
| $
| 720.3
|
|
| $
| 722.5
|
|
| $
| 718.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| As of
|
| |
| September 30,
|
|
| June 30,
|
|
| March 31,
|
|
| December 31,
|
|
| September 30,
|
| |
| 2024 (*)
|
|
| 2024
|
|
| 2024
|
|
| 2023
|
|
| 2023
|
| 12-Month Backlog |
| $
| 4,060
|
|
| $
| 4,250
|
|
| $
| 4,230
|
|
| $
| 4,210
|
|
| $
| 4,150
|
|
(*) Excluding the phase out of certain business activities, in the fourth fiscal quarter of 2024 only. SOURCE: Amdocs - IR View the original press release on accesswire.com
Record Fiscal 2024 Revenue of $5.00 Billion, up 2.4% YoY as Reported and 2.7% YoYin Constant Currency(1) Successfully Achieved Accelerated Profitability Improvement Targets Initiates Fiscal 2025 Outlook: Sharpening Focus on Strategic Priorities while Phasing Out Certain Non-Core, Low Margin Business Activities As a Result of which Expects Fiscal 2025 Revenue Outlook of (10.9)%-(7.7)% YoY as Reported and 1%-4.5% YoY in Pro Forma(2) Constant Currency(1) Targeting Double-Digit Total Shareholder Returns(3)(4), Supported by Enhanced Profitability Improvement Board Approves 10% Increase of Quarterly Cash Dividend(4) Full Year Fiscal 2024 Highlights (All comparisons are against the prior year) Record revenue of $5,005 million, up 2.4% as reported and up 2.7% in constant currency(1), including record revenue of $3,326 million in North America, record revenue of $726 million in Europe and record revenue of $953 million in Rest of World Record managed services revenue of $2,905 million, equivalent to approximately 58% of total revenue GAAP diluted EPS of $4.25, down 5.3%, including a restructuring charge of 98 cents per share, without which GAAP diluted EPS was $5.23 Non-GAAP diluted EPS of $6.44, up 9.0% Free cash flow of $619 million, comprised of cash flow from operations of $724 million, less $105 million in net capital expenditures and other(5), and including $75 million of restructuring payments not assumed in full year free cash flow guidance of $700 million Repurchased $563 million of ordinary shares during the fiscal year Twelve-month backlog of $4.06 billion; adjusting comparable periods for the phase out of certain business activities, twelve-month backlog was up 2.5%(2) as compared to last year's fourth fiscal quarter, and up approximately $30 million(2) sequentially
Fourth Quarter Fiscal 2024 Highlights (All comparisons are against the prior year) Record revenue of $1,264 million, up 1.7% as reported and up 2.1% in constant currency(1); revenue was slightly above the midpoint of the $1,240-$1,280 million guidance range, adjusting for a positive impact from foreign currency movements of approximately $3 million compared to our guidance assumptions GAAP diluted EPS of $0.76, including a restructuring charge of 0.64 cents per share, without which GAAP diluted EPS would have been at the higher end of the guidance range of $1.34-$1.42 Non-GAAP diluted EPS of $1.70, at the midpoint of the guidance range of $1.67-$1.73 GAAP operating income of $113 million, including a restructuring charge of $83 million; GAAP operating margin of 8.9%, down 230 basis points as compared to last year's fourth fiscal quarter and down 520 basis points sequentially Non-GAAP operating income of $236 million; non-GAAP operating margin of 18.7%, up 90 basis points as compared to last year's fourth fiscal quarter and up 10 basis points sequentially, reflecting a continued focus on operational excellence The Board of Directors (the "Board") approved a 10% increase in the Company's quarterly cash dividend payment from $0.479 per share to $0.527 per share, anticipated to be first paid in April 2025, subject to shareholder approval at the January 2025 annual meeting
1. Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
2. For comparison purposes, pro forma adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook
3. Expected total shareholder return assumes midpoint of fiscal year 2025 non-GAAP EPS growth outlook, plus dividend yield
4. Subject to shareholder approval at January 2025 annual meeting
5. Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding) JERSEY CITY, NJ / ACCESSWIRE / November 12, 2024 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended September 30, 2024. "Fiscal 2024 was another important year in our journey as we continued to serve many of the world's largest communication service providers with the innovation they need to accelerate their journey to the cloud, enhance customer experience, monetize next generation networks, and to digitalize and automate their mission critical operations. We delivered strong double-digit growth in cloud, achieved a record year in managed services, and accelerated our profitability, all within the backdrop of a challenging industry demand environment. The year closed with strong sales momentum which included a significant award to deploy our next-gen monetization platform for a major US customer, and new cloud migration deals with Vodafone Italy and NTT Infranet in Japan. Additionally, we have continued to enhance our generative AI platform, amAIz, with new capabilities that leverage NVIDIA AI to deliver immersive customer experiences with real-time interaction and visualization," said Shuky Sheffer, president and chief executive officer of Amdocs Management Limited. "Consistent with our full year guidance, we delivered accelerated profitability improvement in fiscal 2024 as we focused on operational excellence and the benefits of automation and artificial intelligence to drive internal efficiency. We continue to invest in our strategic priorities, while at the same time optimizing the portfolio of products, services, and business activities. Thus, in fiscal 2025, we are phasing out several low-margin, non-core business activities that are becoming commoditized and hold little potential for long-term value addition or profitability enhancement. We believe these actions will reinforce our level of business visibility, including a higher share of revenue from long-term managed services engagements. This move is also expected to sharpen our focus on higher-margin strategic priorities like cloud, monetization platforms and Gen AI where we are well placed to lead the communications industry through our commitment to innovation," said Tamar Rapaport-Dagim, chief financial officer & chief operating officer of Amdocs Management Limited. Sheffer concluded, "We enter fiscal 2025 as an industry leader with a unique competitive position, strong 12-month backlog visibility, and a high win rate. Moreover, we believe Amdocs is well positioned to monetize a healthy pipeline of market opportunities while navigating a continuously challenging demand environment. Adjusting for the phase out of several low-margin, non-core business activities, we expect pro forma(2) revenue growth of between 1% to 4.5% in constant currency(1) in fiscal 2025, as well as another year of double-digit growth in cloud. We also anticipate significantly higher operating profitability and robust earnings to cash conversion, underpinning the delivery of double-digit expected total shareholder returns(3) for the fifth consecutive year, including our dividend yield." Revenue (All comparisons are against the prior year period) | | In millions | | | | Three months ended | | | Twelve months ended | | | | September 30, 2024 | | | September 30, 2024 | | | | Actual | | | Previous
Guidance | | | Actual | | | Previous
Guidance | | | | | | | | | | | | | | | Revenue | | $ | 1,264 | | | $ 1,240-$1,280 | | | $ | 5,005 | | | | - | | Revenue Growth, as reported | | 1.7% | | | | | - | | | 2.4% | | | 1.9%-2.7% | | Revenue Growth, constant currency (1) | | 2.1% | | | | | - | | | 2.7% | | | 2.3%-3.1% | |
Revenue for the fourth fiscal quarter of 2024 was slightly above the midpoint of Amdocs' guidance, adjusting for positive impact from foreign currency movements of approximately $3 million relative to our guidance assumptions and relative to the third quarter of fiscal 2024 Revenue for the full year fiscal 2024 includes an unfavorable impact from foreign currency movements of approximately 0.3% year-over-year
Net Income and Earnings Per Share | | In thousands, expect per share data | | | | Three months ended | | | Twelve months ended | | | | September 30, | | | September 30, | | | | 2024 | | | 2023 | | | 2024 | | | 2023 | | GAAP Measures | | | | | | | | | | | | | Net Income | | $ | 87,176 | | | $ | 102,666 | | | $ | 496,321 | | | $ | 542,962 | | Net Income attributable to Amdocs Limited | | $ | 86,441 | | | $ | 102,011 | | | $ | 493,197 | | | $ | 540,709 | | Diluted earnings per share | | $ | 0.76 | | | $ | 0.86 | | | $ | 4.25 | | | $ | 4.49 | | | | | | | | | | | | | | | | | | | Non-GAAP Measures | | | | | | | | | | | | | | | | | Non-GAAP Net Income | | $ | 195,668 | | | $ | 169,009 | | | $ | 750,928 | | | $ | 714,454 | | Non-GAAP Net Income attributable to Amdocs Limited | | $ | 194,933 | | | $ | 168,354 | | | $ | 747,804 | | | $ | 712,201 | | Non-GAAP Diluted earnings per share | | $ | 1.70 | | | $ | 1.42 | | | $ | 6.44 | | | $ | 5.91 | |
Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below.
Capital Allocation Quarterly Cash Dividend Program: On November 12, 2024, the Board approved the Company's next quarterly cash dividend payment of $0.479 per share, and set December 31, 2024 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on January 31, 2025 The Board also approved a 10% increase in the Company's quarterly cash dividend payment to $0.527 per share, which is anticipated to be first paid in April 2025, provided that the increase is approved by shareholders at the January 2025 annual general meeting of shareholders Share Repurchase Activity: Repurchased $120 million of ordinary shares during the fourth quarter of fiscal 2024
Twelve-month Backlog Twelve-month backlog was $4.06 billion at the end of the fourth quarter of fiscal 2024. On a pro forma(2) basis, adjusting the comparable period for the phase out of certain business activities, twelve-month backlog was up approximately 2.5% as compared to last year's fourth fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities. First Quarter Fiscal 2025 Outlook | | | | | | In millions, expect per share data | | | | Q1 - 2025 | | Revenue | | $ 1,095-$1,135 | | GAAP Diluted earnings per share | | $ 1.20-$1.29 | | Non-GAAP Diluted earnings per share | | $ 1.61-$1.67 | |
First quarter revenue guidance assumes favorable $2 million sequential impact from foreign currency fluctuations as compared to the fourth quarter of fiscal 2024 First quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.20-$0.22 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.11 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects GAAP diluted EPS guidance does not include the impact of future restructuring charges
Full Year Fiscal 2025 Outlook | | | | | | FY 2025 - Year-over -Year growth | | Revenue Growth, as reported | | (10.9)%-(7.7)% | | Revenue Growth, Pro forma (2) constant currency (1) | | 1%-4.5% | | GAAP Diluted earnings per share | | 25.0%-33.0% | | Non-GAAP Diluted earnings per share | | 6.5%-10.5% | | | | | | | | | In millions
FY 2025 | | Free Cash Flow (5) | | $ 710-$730 | |
Revenue growth on a pro forma(2), constant currency(1) basis adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of several low-margin, non-core business activities, including certain low-margin software and hardware partner activities, Vubiquity's transactional video on demand business and non-core subscription services; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook Full year fiscal 2025 revenue guidance incorporates an expected favorable impact from foreign currency fluctuations of approximately 0.2% year-over-year, and includes some inorganic contribution Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.86-$0.94 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.43 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects GAAP diluted EPS guidance does not include the impact of future restructuring charges Non-GAAP operating margin is anticipated to be within a range of 21.1% to 21.7% for the full year fiscal 2025 Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value Non-GAAP effective tax rate is anticipated to be within a range of 15% to 17% for the full year fiscal 2025 Free cash flow(5) is comprised of cash flow from operations, less net capital expenditures and other, and excludes payments related to restructuring charges
The forward looking statements regarding our first fiscal quarter 2025 and full year fiscal 2025 guidance take into consideration the Company's current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. Conference Call and Earnings Webcast Presentation Details Amdocs will host a conference call and earnings webcast presentation on November 12, 2024 at 5:00 p.m. Eastern Time to discuss the Company's fourth quarter of fiscal 2024 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast. Non-GAAP Financial Measures
This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items: amortization of purchased intangible assets and other acquisition-related costs; changes in certain acquisition-related liabilities measured at fair value; restructuring and unusual charges or benefits; equity-based compensation expense; other; and tax effects related to the above.
Free cash flow equals cash generated by operating activities less net capital expenditures and other. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow(5), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business. For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items. Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below. Supporting Resources About Amdocs Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $5.00 billion in fiscal 2024. For more information, visit Amdocs at www.amdocs.com. This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023 and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024, the second quarter of fiscal 2024 filed on May 20, 2024 and for the third quarter of fiscal 2024 on August 19, 2024. Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data) | | Three months ended
September 30, | | | Fiscal year ended
September 30, | | | | 2024 | | | 2023 | | | 2024 | | | 2023 | | Revenue | | $ | 1,263,882 | | | $ | 1,242,564 | | | $ | 5,004,989 | | | $ | 4,887,550 | | Operating expenses: | | | | | | | | | | | | | | | | | Cost of revenue | | | 824,888 | | | | 803,600 | | | | 3,249,598 | | | | 3,159,941 | | Research and development | | | 90,069 | | | | 97,693 | | | | 360,798 | | | | 374,855 | | Selling, general and administrative | | | 138,705 | | | | 140,380 | | | | 572,845 | | | | 570,707 | | Amortization of purchased intangible assets and other | | | 14,333 | | | | 15,601 | | | | 62,052 | | | | 57,156 | | Restructuring charges | | | 83,213 | | | | 46,365 | | | | 131,088 | | | | 70,901 | | | | | 1,151,208 | | | | 1,103,639 | | | | 4,376,381 | | | | 4,233,560 | | Operating income | | | 112,674 | | | | 138,925 | | | | 628,608 | | | | 653,990 | | Interest and other expense, net | | | (9,237 | ) | | | (5,307 | ) | | | (37,537 | ) | | | (17,629 | ) | Income before income taxes | | | 103,437 | | | | 133,618 | | | | 591,071 | | | | 636,361 | | Income taxes | | | 16,261 | | | | 30,952 | | | | 94,750 | | | | 93,399 | | Net income | | $ | 87,176 | | | $ | 102,666 | | | $ | 496,321 | | | $ | 542,962 | | Net income attributable to noncontrolling interests | | | 735 | | | | 655 | | | | 3,124 | | | | 2,253 | | Net income attributable to Amdocs Limited | | $ | 86,441 | | | $ | 102,011 | | | $ | 493,197 | | | $ | 540,709 | | Basic earnings per share attributable to Amdocs Limited | | $ | 0.76 | | | $ | 0.86 | | | $ | 4.27 | | | $ | 4.52 | | Diluted earnings per share attributable to Amdocs Limited | | $ | 0.76 | | | $ | 0.86 | | | $ | 4.25 | | | $ | 4.49 | | Basic weighted average number of shares outstanding | | | 113,745 | | | | 118,076 | | | | 115,489 | | | | 119,687 | | Diluted weighted average number of shares outstanding | | | 114,378 | | | | 118,884 | | | | 116,145 | | | | 120,519 | | Cash dividends declared per share | | $ | 0.479 | | | $ | 0.435 | | | $ | 1.872 | | | $ | 1.700 | |
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data) | | Three months ended
September 30, | | | Fiscal year ended
September 30, | | | | 2024 | | | 2023 | | | 2024 | | | 2023 | | | | | | | | | | | | | | | Revenue | | $ | 1,263,882 | | | $ | 1,242,564 | | | $ | 5,004,989 | | | $ | 4,887,550 | | Non-GAAP operating income | | | 236,223 | | | | 221,105 | | | | 923,288 | | | | 868,602 | | Non-GAAP net income | | | 195,668 | | | | 169,009 | | | | 750,928 | | | | 714,454 | | Non-GAAP net income attributable to Amdocs Limited | | | 194,933 | | | | 168,354 | | | | 747,804 | | | | 712,201 | | Non-GAAP diluted earnings per share | | $ | 1.70 | | | $ | 1.42 | | | $ | 6.44 | | | $ | 5.91 | | Diluted weighted average number of shares outstanding | | | 114,378 | | | | 118,884 | | | | 116,145 | | | | 120,519 | |
Free Cash Flows
(In thousands) | | Three months ended
September 30, | | | Fiscal year ended
September 30, | | | | 2024 | | | 2023 | | | 2024 | | | 2023 | | | | | | | | | | | | | | | Net Cash Provided by Operating Activities | | $ | 217,922 | | | $ | 272,371 | | | $ | 724,428 | | | $ | 822,630 | | Purchases of property and equipment, net (a) | | | (25,812 | ) | | | (26,557 | ) | | | (105,495 | ) | | | (124,362 | ) | Free Cash Flow | | $ | 192,110 | | | $ | 245,814 | | | $ | 618,933 | | | $ | 698,268 | |
(a) The amounts under "Purchase of property and equipment, net" include immaterial proceeds from sale of property and equipment for the fiscal years ended September 30, 2024 and 2023, respectively. AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands) | | Three Months Ended September 30, 2024 | | | | GAAP | | | Amortization of purchased intangible assets and other | | | Equity based compensation expense | | | Restructuring charges | | | Other | | | Tax
effect | | | Non-GAAP | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | Cost of revenue | | $ | 824,888 | | | $ | - | | | $ | (13,283 | ) | | $ | - | | | $ | - | | | $ | - | | | $ | 811,605 | | Research and development | | | 90,069 | | | | | | | | (2,355 | ) | | | | | | | | | | | | | | | 87,714 | | Selling, general and administrative | | | 138,705 | | | | | | | | (10,365 | ) | | | | | | | | | | | | | | | 128,340 | | Amortization of purchased intangible assets and other | | | 14,333 | | | | (14,333 | ) | | | | | | | | | | | | | | | | | | | - | | Restructuring charges | | | 83,213 | | | | | | | | | | | | (83,213 | ) | | | | | | | | | | | - | | Total operating expenses | | | 1,151,208 | | | | (14,333 | ) | | | (26,003 | ) | | | (83,213 | ) | | | | | | | | | | | 1,027,659 | | Operating income | | | 112,674 | | | | 14,333 | | | | 26,003 | | | | 83,213 | | | | | | | | | | | | 236,223 | | Interest and other expense, net | | | (9,237 | ) | | | | | | | | | | | | | | | 2,549 | | | | | | | | (6,688 | ) | Income taxes | | | 16,261 | | | | | | | | | | | | | | | | | | | | 17,606 | | | | 33,867 | | Net income | | | 87,176 | | | | 14,333 | | | | 26,003 | | | | 83,213 | | | | 2,549 | | | | (17,606 | ) | | | 195,668 | | Net income attributable to noncontrolling interests | | | 735 | | | | | | | | | | | | | | | | | | | | | | | | 735 | | Net income attributable to Amdocs Limited | | $ | 86,441 | | | $ | 14,333 | | | $ | 26,003 | | | $ | 83,213 | | | $ | 2,549 | | | $ | (17,606 | ) | | $ | 194,933 | |
| | Three Months Ended September 30, 2023 | | | | GAAP | | | Amortization of purchased intangible assets and other | | | Equity based compensation expense | | | Changes in certain acquisitions related liabilities measured at fair value | | | Restructuring charges | | | Other | | | Tax
effect | | | Non-GAAP | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | Cost of revenue | | $ | 803,600 | | | $ | - | | | $ | (12,401 | ) | | $ | 4,579 | | | $ | - | | | $ | - | | | $ | - | | | $ | 795,778 | | Research and development | | | 97,693 | | | | | | | | (2,285 | ) | | | | | | | | | | | | | | | | | | | 95,408 | | Selling, general and administrative | | | 140,380 | | | | | | | | (10,107 | ) | | | | | | | | | | | | | | | | | | | 130,273 | | Amortization of purchased intangible assets and other | | | 15,601 | | | | (15,601 | ) | | | | | | | | | | | | | | | | | | | | | | | - | | Restructuring charges | | | 46,365 | | | | | | | | | | | | | | | | (46,365 | ) | | | | | | | | | | | - | | Total operating expenses | | | 1,103,639 | | | | (15,601 | ) | | | (24,793 | ) | | | 4,579 | | | | (46,365 | ) | | | | | | | | | | | 1,021,459 | | Operating income | | | 138,925 | | | | 15,601 | | | | 24,793 | | | | (4,579 | ) | | | 46,365 | | | | | | | | | | | | 221,105 | | Interest and other expense, net | | | (5,307 | ) | | | | | | | | | | | | | | | | | | | 398 | | | | | | | | (4,909 | ) | Income taxes | | | 30,952 | | | | | | | | | | | | | | | | | | | | | | | | 16,235 | | | | 47,187 | | Net income | | | 102,666 | | | | 15,601 | | | | 24,793 | | | | (4,579 | ) | | | 46,365 | | | | 398 | | | | (16,235 | ) | | | 169,009 | | Net income attributable to noncontrolling interests | | | 655 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 655 | | Net income attributable to Amdocs Limited | | $ | 102,011 | | | $ | 15,601 | | | $ | 24,793 | | | $ | (4,579 | ) | | $ | 46,365 | | | $ | 398 | | | $ | (16,235 | ) | | $ | 168,354 | |
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands) | | Fiscal year ended September 30,2024 | | | | GAAP | | | Amortization of purchased intangible assets and other | | | Equity based compensation expense | | | Changes in certain acquisitions related liabilities measured at fair value | | | Restructuring charges | | | Other | | | Tax
effect | | | Non-GAAP | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | Cost of revenue | | $ | 3,249,598 | | | $ | - | | | $ | (53,409 | ) | | $ | 3,000 | | | $ | - | | | $ | - | | | $ | - | | | $ | 3,199,189 | | Research and development | | | 360,798 | | | | | | | | (8,644 | ) | | | | | | | | | | | | | | | | | | | 352,154 | | Selling, general and administrative | | | 572,845 | | | | | | | | (42,487 | ) | | | | | | | | | | | | | | | | | | | 530,358 | | Amortization of purchased intangible assets and other | | | 62,052 | | | | (62,052 | ) | | | | | | | | | | | | | | | | | | | | | | | - | | Restructuring charges | | | 131,088 | | | | | | | | | | | | | | | | (131,088 | ) | | | | | | | | | | | - | | Total operating expenses | | | 4,376,381 | | | | (62,052 | ) | | | (104,540 | ) | | | 3,000 | | | | (131,088 | ) | | | | | | | | | | | 4,081,701 | | Operating income | | | 628,608 | | | | 62,052 | | | | 104,540 | | | | (3,000 | ) | | | 131,088 | | | | | | | | | | | | 923,288 | | Interest and other expense, net | | | (37,537 | ) | | | | | | | | | | | | | | | | | | | 8,087 | | | | | | | | (29,450 | ) | Income taxes | | | 94,750 | | | | | | | | | | | | | | | | | | | | | | | | 48,160 | | | | 142,910 | | Net income | | | 496,321 | | | | 62,052 | | | | 104,540 | | | | (3,000 | ) | | | 131,088 | | | | 8,087 | | | | (48,160 | ) | | | 750,928 | | Net income attributable to noncontrolling interests | | | 3,124 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,124 | | Net income attributable to Amdocs Limited | | $ | 493,197 | | | $ | 62,052 | | | $ | 104,540 | | | $ | (3,000 | ) | | $ | 131,088 | | | $ | 8,087 | | | $ | (48,160 | ) | | $ | 747,804 | |
| | Fiscal year ended September 30,2023 | | | | | | | GAAP | | | Amortization of purchased intangible assets and other | | | Equity based compensation expense | | | Changes in certain acquisitions related liabilities measured at fair value | | | Restructuring charges | | | Other | | | Tax
effect | | | Non-GAAP | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | Cost of revenue | | $ | 3,159,941 | | | $ | - | | | $ | (42,969 | ) | | $ | 3,143 | | | $ | - | | | $ | - | | | $ | - | | | $ | 3,120,115 | | Research and development | | | 374,855 | | | | | | | | (7,509 | ) | | | | | | | | | | | | | | | | | | | 367,346 | | Selling, general and administrative | | | 570,707 | | | | | | | | (39,220 | ) | | | | | | | | | | | | | | | | | | | 531,487 | | Amortization of purchased intangible assets and other | | | 57,156 | | | | (57,156 | ) | | | | | | | | | | | | | | | | | | | | | | | - | | Restructuring charges | | | 70,901 | | | | | | | | | | | | | | | | (70,901 | ) | | | | | | | | | | | - | | Total operating expenses | | | 4,233,560 | | | | (57,156 | ) | | | (89,698 | ) | | | 3,143 | | | | (70,901 | ) | | | | | | | | | | | 4,018,948 | | Operating income | | | 653,990 | | | | 57,156 | | | | 89,698 | | | | (3,143 | ) | | | 70,901 | | | | | | | | | | | | 868,602 | | Interest and other expense, net | | | (17,629 | ) | | | | | | | | | | | | | | | | | | | 906 | | | | | | | | (16,723 | ) | Income taxes | | | 93,399 | | | | | | | | | | | | | | | | | | | | | | | | 44,026 | | | | 137,425 | | Net income | | | 542,962 | | | | 57,156 | | | | 89,698 | | | | (3,143 | ) | | | 70,901 | | | | 906 | | | | (44,026 | ) | | | 714,454 | | Net income attributable to noncontrolling interests | | | 2,253 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,253 | | Net income attributable to Amdocs Limited | | $ | 540,709 | | | $ | 57,156 | | | $ | 89,698 | | | $ | (3,143 | ) | | $ | 70,901 | | | $ | 906 | | | $ | (44,026 | ) | | $ | 712,201 | |
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands) | | As of | | | | September 30,
2024 | | | September 30,
2023 | | ASSETS | | | | | | | Current assets: | | | | | | | Cash and cash equivalents | | $ | 346,085 | | | $ | 520,080 | | Short-term interest-bearing investments | | | 168,242 | | | | 222,451 | | Accounts receivable, net, including unbilled | | | 1,028,357 | | | | 944,477 | | Prepaid expenses and other current assets | | | 228,498 | | | | 224,622 | | Total current assets | | | 1,771,182 | | | | 1,911,630 | | | | | | | | | | | Property and equipment, net | | | 755,601 | | | | 790,923 | | Lease assets | | | 149,254 | | | | 160,938 | | Goodwill and other intangible assets, net | | | 3,005,637 | | | | 2,930,580 | | Other noncurrent assets | | | 704,468 | | | | 631,582 | | Total assets | | $ | 6,386,142 | | | $ | 6,425,653 | | | | | | | | | | | LIABILITIES AND SHAREHOLDERS' EQUITY | | | | | | | | | | | | | | | | | | Current liabilities | | | | | | | | | Accounts payable, accruals and other | | $ | 1,315,679 | | | $ | 1,142,781 | | Lease liabilities | | | 39,983 | | | | 39,960 | | Deferred revenue | | | 115,247 | | | | 170,634 | | Total current liabilities | | | 1,470,909 | | | | 1,353,375 | | Lease liabilities | | | 103,462 | | | | 121,654 | | Long-term debt, net of unamortized debt issuance costs | | | 646,291 | | | | 645,696 | | Other noncurrent liabilities | | | 666,303 | | | | 737,996 | | Total Amdocs Limited Shareholders' equity | | | 3,456,976 | | | | 3,523,759 | | Noncontrolling interests | | | 42,201 | | | | 43,173 | | Total equity | | | 3,499,177 | | | | 3,566,932 | | Total liabilities and equity | | $ | 6,386,142 | | | $ | 6,425,653 | |
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands) | | Fiscal year ended
September 30, | | | | 2024 | | | 2023 | | Cash Flow from Operating Activities: | | | | | | | Net income | | $ | 496,321 | | | $ | 542,962 | | Reconciliation of net income to net cash provided by operating activities: | | | | | | | | | Depreciation, amortization and impairment | | | 193,066 | | | | 195,701 | | Amortization of debt issuance cost | | | 596 | | | | 579 | | Equity-based compensation expense | | | 104,540 | | | | 89,698 | | Deferred income taxes | | | (45,673 | ) | | | (60,212 | ) | Loss from short-term interest-bearing investments | | | 5,576 | | | | 2,762 | | Net changes in operating assets and liabilities, net of amounts acquired: | | | | | | | | | Accounts receivable, net | | | (104,413 | ) | | | 3,457 | | Prepaid expenses and other current assets | | | (8,478 | ) | | | 7,891 | | Other noncurrent assets | | | (2,250 | ) | | | (1,532 | ) | Lease assets and liabilities, net | | | (6,485 | ) | | | (4,144 | ) | Accounts payable, accrued expenses and accrued personnel | | | 216,324 | | | | 158,876 | | Deferred revenue | | | (60,332 | ) | | | (157,829 | ) | Income taxes payable, net | | | (47,241 | ) | | | (11,596 | ) | Other noncurrent liabilities | | | (17,123 | ) | | | 56,017 | | Net cash provided by operating activities | | | 724,428 | | | | 822,630 | | Cash Flow from Investing Activities: | | | | | | | | | Purchase of property and equipment, net(a) | | | (105,495 | ) | | | (124,362 | ) | Proceeds from sale of short-term interest-bearing investments | | | 68,659 | | | | 25,984 | | Purchase of short-term interest-bearing investments | | | (9,061 | ) | | | - | | Net cash paid for business and intangible assets acquisitions | | | (86,824 | ) | | | (121,818 | ) | Other | | | 5,315 | | | | (4,301 | ) | Net cash used in investing activities | | | (127,406 | ) | | | (224,497 | ) | Cash Flow from Financing Activities: | | | | | | | | | Repurchase of shares | | | (563,121 | ) | | | (489,524 | ) | Proceeds from employee stock option exercises | | | 26,949 | | | | 48,681 | | Payments of dividends | | | (211,967 | ) | | | (199,460 | ) | Distribution to noncontrolling interests | | | (4,096 | ) | | | (1,589 | ) | Payment of contingent consideration from a business acquisition | | | (18,782 | ) | | | (9,538 | ) | Net cash used in financing activities | | | (771,017 | ) | | | (651,430 | ) | Net decrease in cash and cash equivalents | | | (173,995 | ) | | | (53,297 | ) | Cash and cash equivalents at beginning of year | | | 520,080 | | | | 573,377 | | Cash and cash equivalents at end of year | | $ | 346,085 | | | $ | 520,080 | |
AMDOCS LIMITED
Supplementary Information
(In millions) | | Three months ended | | | | September 30, | | | June 30, | | | March 31, | | | December 31, | | | September 30, | | | | 2024 | | | 2024 | | | 2024 | | | 2023 | | | 2023 | | North America | | $ | 835.8 | | | $ | 828.8 | | | $ | 823.2 | | | $ | 838.1 | | | $ | 834.4 | | Europe | | | 184.1 | | | | 175.9 | | | | 184.8 | | | | 181.4 | | | | 175.5 | | Rest of the World | | | 244.0 | | | | 245.3 | | | | 237.8 | | | | 225.7 | | | | 232.6 | | Total Revenue | | $ | 1,263.9 | | | $ | 1,250.1 | | | $ | 1,245.8 | | | $ | 1,245.2 | | | $ | 1,242.6 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | Three months ended | | | | September 30, | | | June 30, | | | March 31, | | | December 31, | | | September 30, | | | | 2024 | | | 2024 | | | 2024 | | | 2023 | | | 2023 | | Managed Services Revenue | | $ | 721.4 | | | $ | 740.8 | | | $ | 720.3 | | | $ | 722.5 | | | $ | 718.1 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | As of | | | | September 30, | | | June 30, | | | March 31, | | | December 31, | | | September 30, | | | | 2024 (*) | | | 2024 | | | 2024 | | | 2023 | | | 2023 | | 12-Month Backlog | | $ | 4,060 | | | $ | 4,250 | | | $ | 4,230 | | | $ | 4,210 | | | $ | 4,150 | |
(*) Excluding the phase out of certain business activities, in the fourth fiscal quarter of 2024 only. SOURCE: Amdocs - IR View the original press release on accesswire.com
|